The March 2026 amendment to IP0420 clarifies that BMI and comorbidity assessments must be measured at baseline (prior to initiating the requested weight-loss medication) and explicitly lists asthma and COPD among acceptable weight-related comorbidities for the BMI ≥27 pathway. The policy removes the prior “failed to achieve desired weight loss” language and instead requires documented engagement in behavioral modification and dietary restriction for at least 3 months, with all weight-loss medications to be used concomitantly with behavioral modification and a reduced-calorie diet. Product-specific initial approval durations and age limits are specified (e.g., phentermine 3 months, Contrave 4 months, Qsymia 6 months; pediatric criteria for Qsymia and orlistat included), and continuing therapy generally requires meeting baseline criteria and often ≥5% weight loss from baseline (baseline defined as pre-treatment) for renewals. Preferred product/formulary checks are embedded for certain agents and continuing approvals are typically granted for one year when criteria are met.
March 2026 Revision: Baseline BMI and Behavioral Trial Language Clarified in `IP0420`
Summary of Revisions in this Amendment to IP0420
This revision clarifies and tightens baseline BMI and comorbidity language across multiple appetite suppressant and orlistat indications. The prior requirement that patients must have "failed to achieve the desired weight loss" after a behavioral modification trial was removed; instead the policy now requires that patients have "engaged in a trial of behavioral modification and dietary restriction for at least 3 months" without a fail requirement. Multiple instances in the document emphasize that BMI and comorbidity determinations are measured "at baseline," with an explicit Note added that baseline refers to the time prior to initiation of the requested weight-loss medication (for example, prior to phentermine hydrochloride, Contrave, Qsymia, or orlistat).
Specific changes called out in the revision details
- The BMI criterion was changed uniformly to require that the patient "at baseline" had a BMI ≥ 30 kg/m2, or "at baseline" had a BMI ≥ 27 kg/m2 plus at least one specified weight-related comorbidity (the policy lists hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease, knee osteoarthritis, asthma, chronic obstructive pulmonary disease, metabolic-dysfunction associated steatotic liver disease/non-alcoholic fatty liver disease, polycystic ovarian syndrome, or coronary artery disease). A Note was added to clarify that baseline refers to the time prior to the requested medication.
- The language requiring that the patient must have "failed to achieve the desired weight loss" after behavioral modification was removed; the policy now requires documented engagement in behavioral modification and dietary restriction for at least 3 months and that the medication "will be used concomitantly with behavioral modification and a reduced-calorie diet."
- For continuing therapy criteria that require ≥ 5% weight loss, a Note was added clarifying the reference baseline as baseline prior to the requested medication.
Product-specific Eligibility Durations and Age Criteria in `IP0420`
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.